Table 2 The in vivo assessment of H. pylori cure rates of pexiganan-conjugated lipid-liquid crystals
Drug formula | Dose (mg.kg) | Cure rate | Mean bacterial count (Log CFU/stomach) |
|---|---|---|---|
Placebo | NA | 0/6 (0%) | 7.78 ± 0.61 |
NMP | NA | 0/6 (0%) | 7.18 ± 0.37 |
GDO | NA | 0/6 (0%) | 7.23 ± 0.56 |
Pexiganan | 2 | 0/6 (0%) | 6.68 ± 0.12 |
Pexiganan | 5 | 0/6 (0%) | 6.28 ± 0.35 |
Pexiganan | 10 | 2/6 (33.3%) | 4.26 ± 0.18 |
Clarithromycin | 20 | 5/6 (83.3%) | 2.16 ± 0.57 |
Clarithromycin:Pexiganan | 20:10 | 6/6 (100%) | 0 |
Clarithromycin:LLC | 20 | 6/6 (100%) | 0 |
Pexiganan:LLC | 2 | 1/6 (17%) | 5.12 ± 0.36 |
Pexiganan:LLC | 5 | 2/6 (33.3%) | 4.82 ± 0.16 |
Pexiganan:LLC | 10 | 4/6 (67%) | 3.61 ± 0.23 |